540 related articles for article (PubMed ID: 22310599)
1. The efficacy and safety of high-dose mizoribine in ABO-incompatible kidney transplantation using anti-CD20 and anti-CD25 antibody without splenectomy treatment.
Yoshimura N; Ushigome H; Matsuyama M; Nobori S; Suzuki T; Sakai K; Okajima H; Okamoto M
Transplant Proc; 2012 Jan; 44(1):140-3. PubMed ID: 22310599
[TBL] [Abstract][Full Text] [Related]
2. Usefulness and safety of high-dose mizoribine on ABO-incompatible living related kidney transplantation using anti-CD20 and anti-CD25 antibodies without splenectomy: 3-year results.
Yoshimura N; Ushigome H; Nobori S; Suzuki T; Sakai K; Koshino K; Nakamura T; Nakao T; Harada S; Ito T
Transplant Proc; 2014; 46(2):391-4. PubMed ID: 24655971
[TBL] [Abstract][Full Text] [Related]
3. The excellent outcomes of ABO-incompatible kidney transplantation with high titer (>×2048) using anti-CD20 and anti-CD25 antibody without splenectomy: two case reports.
Koshino K; Okamoto M; Sakai K; Suzuki T; Nobori S; Matsuyama M; Ushigome H; Okajima H; Yoshimura N
Transplant Proc; 2011; 43(6):2379-82. PubMed ID: 21839272
[TBL] [Abstract][Full Text] [Related]
4. Pinpoint targeted immunosuppression: anti-CD20/MMF desensitization with anti-CD25 in successful ABO-incompatible kidney transplantation without splenectomy.
Saito K; Nakagawa Y; Suwa M; Kumagai N; Tanikawa T; Nishiyama T; Ueno M; Gejyo F; Nishi S; Takahashi K
Xenotransplantation; 2006 Mar; 13(2):111-7. PubMed ID: 16623803
[TBL] [Abstract][Full Text] [Related]
5. The beneficial effect of high-dose mizoribine combined with cyclosporine, basiliximab, and corticosteroids on CMV infection in renal transplant recipients.
Yoshimura N; Ushigome H; Akioka K; Nobori S; Suzuki T; Sakai K; Okamoto M
Clin Exp Nephrol; 2013 Feb; 17(1):127-33. PubMed ID: 23011290
[TBL] [Abstract][Full Text] [Related]
6. Neither pre-transplant rituximab nor splenectomy affects de novo HLA antibody production after renal transplantation.
Ashimine S; Watarai Y; Yamamoto T; Hiramitsu T; Tsujita M; Nanmoku K; Goto N; Takeda A; Katayama A; Uchida K; Kobayashi T
Kidney Int; 2014 Feb; 85(2):425-30. PubMed ID: 23945498
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of 2 Doses of Rituximab on B-Cell and Antidonor Antibody and Outcomes of ABO-Incompatible Living-Donor Pediatric Kidney Transplant.
Hamasaki Y; Aikawa A; Itabashi Y; Muramatsu M; Hyoudou Y; Shinoda K; Takahashi Y; Sakurabayashi K; Mizutani T; Oguchi H; Kawamura T; Sakai K; Shishido S
Exp Clin Transplant; 2019 Jan; 17(Suppl 1):105-109. PubMed ID: 30777532
[TBL] [Abstract][Full Text] [Related]
8. The 5-year outcome of ABO-incompatible kidney transplantation with rituximab induction.
Fuchinoue S; Ishii Y; Sawada T; Murakami T; Iwadoh K; Sannomiya A; Koyama I; Kubota K; Tojimbara T; Nakajima I; Teraoka S
Transplantation; 2011 Apr; 91(8):853-7. PubMed ID: 21297552
[TBL] [Abstract][Full Text] [Related]
9. Results of a multicenter prospective clinical study in Japan for evaluating efficacy and safety of desensitization protocol based on rituximab in ABO-incompatible kidney transplantation.
Takahashi K; Saito K; Takahara S; Fuchinoue S; Yagisawa T; Aikawa A; Watarai Y; Yoshimura N; Tanabe K; Morozumi K; Shimazu M;
Clin Exp Nephrol; 2017 Aug; 21(4):705-713. PubMed ID: 27534951
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of High-Dose Mizoribine Combined With Cyclosporine, Basiliximab, and Corticosteroids in Renal Transplantation: A Japanese Multicenter Study.
Ushigome H; Uchida K; Nishimura K; Akioka K; Fukuda Y; Yuzawa K; Fujisawa M; Sugitani A; Ito SI; Nakatani T; Horimi T; Yoshimura N
Transplant Proc; 2016 Apr; 48(3):794-8. PubMed ID: 27234738
[TBL] [Abstract][Full Text] [Related]
11. Excellent results with high-dose mizoribine combined with cyclosporine, corticosteroid, and basiliximab in renal transplant recipients: multicenter study in Japan.
Nishimura K; Uchida K; Yuzawa K; Fukuda Y; Ichikawa Y; Akioka K; Fujisawa M; Sugitani A; Ito S; Nakatani T; Horimi T; Yoshimura N
Transplant Proc; 2012 Jan; 44(1):147-9. PubMed ID: 22310601
[TBL] [Abstract][Full Text] [Related]
12. Potent immunosuppression for ABO-incompatible renal transplantation may not be a risk factor for malignancy.
Yamamoto T; Kawaguchi T; Watarai Y; Tujita M; Hiramitsu T; Nanmoku K; Goto N; Katayama A; Kobayashi T; Uchida K
Transplant Proc; 2012 Jan; 44(1):210-3. PubMed ID: 22310616
[TBL] [Abstract][Full Text] [Related]
13. Living donor kidney transplantation in patients with donor-specific HLA antibodies enabled by anti-CD20 therapy and peritransplant apheresis.
Klein K; Süsal C; Schäfer SM; Becker LE; Beimler J; Schwenger V; Zeier M; Schemmer P; Macher-Goeppinger S; Scherer S; Opelz G; Morath C
Atheroscler Suppl; 2013 Jan; 14(1):199-202. PubMed ID: 23357165
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of blood group antibodies in ABO-incompatible living-donor kidney transplantation.
Sugiyama K; Hyodo Y; Aikawa A
Int J Urol; 2015 Oct; 22(10):931-6. PubMed ID: 26108258
[TBL] [Abstract][Full Text] [Related]
15. Kidney transplantation of living unrelated donor-recipient combinations.
Ishikawa N; Yagisawa T; Sakuma Y; Fujiwara T; Kimura T; Nukui A; Yashi M
Transplant Proc; 2012 Jan; 44(1):254-6. PubMed ID: 22310625
[TBL] [Abstract][Full Text] [Related]
16. Experiences and problems pre-operative anti-CD20 monoclonal antibody infusion therapy with splenectomy and plasma exchange for ABO-incompatible living-donor liver transplantation.
Usui M; Isaji S; Mizuno S; Sakurai H; Uemoto S
Clin Transplant; 2007; 21(1):24-31. PubMed ID: 17302588
[TBL] [Abstract][Full Text] [Related]
17. Long-term recurrence-free survival after liver transplantation from an ABO-incompatible living donor for treatment of hepatocellular carcinoma exceeding Milano criteria in a patient with hepatitis B virus cirrhosis: a case report.
Nakamura Y; Hama K; Iwamoto H; Yokoyama T; Kihara Y; Konno O; Jojima Y; Shimazu M
Transplant Proc; 2012 Mar; 44(2):565-9. PubMed ID: 22410070
[TBL] [Abstract][Full Text] [Related]
18. ABO-incompatible live donor renal transplantation using blood group A/B carbohydrate antigen immunoadsorption and anti-CD20 antibody treatment.
Nordén G; Briggs D; Cockwell P; Lipkin G; Mjörnstedt L; Mölne J; Ready A; Rydberg L; Samuelsson O; Svalander CT; Breimer ME
Xenotransplantation; 2006 Mar; 13(2):148-53. PubMed ID: 16623810
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of two different preconditioning regimens for ABO-incompatible living kidney donor transplantation. A comparison of splenectomy vs. rituximab-treated non-splenectomy preconditioning regimens.
Tanabe K; Ishida H; Shimizu T; Omoto K; Shirakawa H; Tokumoto T
Contrib Nephrol; 2009; 162():61-74. PubMed ID: 19001814
[TBL] [Abstract][Full Text] [Related]
20. Excellent results of high-dose mizoribine combined with cyclosporine, basiliximab, and corticosteroids in renal transplant recipients--4-year results.
Yoshimura N; Ushigome H; Nobori S; Suzuki T; Sakai K; Koshino K; Okajima H; Okamoto M
Transplant Proc; 2013 May; 45(4):1472-5. PubMed ID: 23726600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
